Charme Capital Partners SGR has acquired a majority stake in Bianalisi, a leading Italian laboratory diagnostics provider, aiming to enhance growth and service expansion within the fragmented healthcare sector.

Target Overview

Bianalisi is a prominent entity in the laboratory diagnostics, outpatient services, and diagnostic imaging sector in Italy. Established in 1968 and headquartered in Carate Brianza, the company rose to prominence under the leadership of entrepreneur Giuliano Caslini after its acquisition in 2000. Over the past two decades, Bianalisi has executed a considerable expansion strategy primarily through acquisitions, thereby positioning itself among Italy's leading healthcare providers.

Currently, Bianalisi operates over 260 laboratories and more than 50 outpatient clinics across nine Italian regions, serving approximately 13,000 patients daily. The company conducts over 50,000 laboratory tests and 2,000 specialist medical examinations each day, supported by a team of over 600 medical professionals. In the year 2020 alone, Bianalisi performed over 16 million laboratory tests and offers advanced diagnostic imaging services utilizing cutting-edge equipment such as CT and MRI. This extensive network and reputation for quality healthcare make Bianalisi a key player in Italy's health services landscape.

Industry Overview

The healthcare sector in Italy, particularly the diagnostics market, is characterized by its fragmentation, making it one of the most diverse and competitive environments in Europe. The Italian diagnostics market is poised for consolidation,